Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

REX CAMPBELL GARLAND

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1902241813
CMS profile
673872
Location
TEMPLE, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$403.03

4 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $305.03 3
Education $98.00 1

By paying entity

PY2024 · entire year · sorted by reported total

Paying entityAmountRecords
Apellis Pharmaceuticals, Inc. $119.27 1
Astellas Pharma US Inc $98.00 1
PFIZER INC. $97.04 1
Janssen Scientific Affairs, LLC $88.72 1

Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

REX CAMPBELL GARLAND

NPI 1902241813 · CMS profile ID 673872

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

TEMPLE, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1902241813?year=2024&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
REX CAMPBELL GARLAND, NPI 1902241813, CMS profile ID 673872. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1902241813?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). REX CAMPBELL GARLAND, NPI 1902241813, CMS profile ID 673872. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1902241813?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
REX CAMPBELL GARLAND, NPI 1902241813, CMS profile ID 673872, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1902241813?year=2024&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

4 matching records · $403.03 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 4 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–4 of 4.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
PFIZER INC. $97.0412/08/2024 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1155252632 CMS
Astellas Pharma US Inc $98.0005/01/2024 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139348924 CMS
Janssen Scientific Affairs, LLC $88.7204/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078860899 CMS
Apellis Pharmaceuticals, Inc. $119.2701/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1154028173 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $114.32 1
PY2020 $70.31 1
PY2021 $153.45 6
PY2022 $127.77 2
PY2023 $507.82 5
PY2024 $403.03 4
PY2025 $190.17 2

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $965,516.14 86
PY2024 Principal investigator $293,948.30 30
PY2023 Principal investigator $62,636.64 9
PY2022 Principal investigator $43,443.95 10
PY2021 Principal investigator $129,407.72 30
PY2020 Principal investigator $118,313.60 29

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

29 records in PY2020

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 TerSera Therapeutics LLC $187.51 12/17/2020 Covered Recipient Teaching Hospital
SCOTT AND WHITE MEMORIAL HOSPITAL
A Phase 2 Exploratory Study of Intravenous Quzyttir (Cetirizine HCl Injection) Versus IV Diphenhydramine in the Prevention of Hypersesitivity Infusion Reactions No dispute reported 06/30/2026 748252579
Principal investigator 1 GlaxoSmithKline, LLC. $1,000.00 11/16/2020 Non-covered Recipient Entity
BAYLOR RESEARCH INSTITUTE
DREAMM 7: A MULTICENTER, OPEN-LABEL, RANDOMIZED PHASE III STUDY TO EVA No dispute reported 06/30/2026 734919269
Principal investigator 1 GlaxoSmithKline, LLC. $750.00 11/16/2020 Non-covered Recipient Entity
BAYLOR RESEARCH INSTITUTE
DREAMM 7: A MULTICENTER, OPEN-LABEL, RANDOMIZED PHASE III STUDY TO EVA No dispute reported 06/30/2026 734920831
Principal investigator 1 GlaxoSmithKline, LLC. $14,000.00 11/13/2020 Non-covered Recipient Entity
BAYLOR RESEARCH INSTITUTE
DREAMM 7: A MULTICENTER, OPEN-LABEL, RANDOMIZED PHASE III STUDY TO EVA No dispute reported 06/30/2026 734907945
Principal investigator 1 GlaxoSmithKline, LLC. $2,373.00 11/13/2020 Non-covered Recipient Entity
BAYLOR RESEARCH INSTITUTE
DREAMM 7: A MULTICENTER, OPEN-LABEL, RANDOMIZED PHASE III STUDY TO EVA No dispute reported 06/30/2026 734912503
Principal investigator 1 GlaxoSmithKline, LLC. $4,000.00 11/13/2020 Non-covered Recipient Entity
BAYLOR RESEARCH INSTITUTE
DREAMM 7: A MULTICENTER, OPEN-LABEL, RANDOMIZED PHASE III STUDY TO EVA No dispute reported 06/30/2026 734923265
Principal investigator 1 GlaxoSmithKline, LLC. $1,500.00 11/13/2020 Non-covered Recipient Entity
BAYLOR RESEARCH INSTITUTE
DREAMM 7: A MULTICENTER, OPEN-LABEL, RANDOMIZED PHASE III STUDY TO EVA No dispute reported 06/30/2026 734924331
Principal investigator 1 GlaxoSmithKline, LLC. $1,500.00 11/13/2020 Non-covered Recipient Entity
BAYLOR RESEARCH INSTITUTE
DREAMM 7: A MULTICENTER, OPEN-LABEL, RANDOMIZED PHASE III STUDY TO EVA No dispute reported 06/30/2026 734928953
Principal investigator 1 GlaxoSmithKline, LLC. $1,817.78 10/16/2020 Non-covered Recipient Entity
BAYLOR RESEARCH INSTITUTE
DREAMM 7: A MULTICENTER, OPEN-LABEL, RANDOMIZED PHASE III STUDY TO EVA No dispute reported 06/30/2026 734911629
Principal investigator 1 Secura Bio, Inc. $468.00 10/08/2020 Non-covered Recipient Entity
BAYLOR RESEARCH INSTITUTE
VS-0145-229 No dispute reported 06/30/2026 753201803
Principal investigator 1 Verastem, Inc. $23,871.60 09/14/2020 Non-covered Recipient Entity
BAYLOR RESEARCH INSTITUTE
VS-0145-229 No dispute reported 06/30/2026 745013349
Principal investigator 1 Verastem, Inc. $963.42 09/14/2020 Non-covered Recipient Entity
BAYLOR RESEARCH INSTITUTE
VS-0145-229 No dispute reported 06/30/2026 745013355
Principal investigator 1 Verastem, Inc. $468.00 09/14/2020 Non-covered Recipient Entity
BAYLOR RESEARCH INSTITUTE
VS-0145-229 No dispute reported 06/30/2026 745013361
Principal investigator 1 GlaxoSmithKline, LLC. $1,000.00 08/19/2020 Non-covered Recipient Entity
BAYLOR RESEARCH INSTITUTE
DREAMM 7: A MULTICENTER, OPEN-LABEL, RANDOMIZED PHASE III STUDY TO EVA No dispute reported 06/30/2026 734910103
Principal investigator 1 GlaxoSmithKline, LLC. $750.00 08/19/2020 Non-covered Recipient Entity
BAYLOR RESEARCH INSTITUTE
DREAMM 7: A MULTICENTER, OPEN-LABEL, RANDOMIZED PHASE III STUDY TO EVA No dispute reported 06/30/2026 734918007
Principal investigator 1 Celgene Corporation $19,750.00 08/06/2020 Covered Recipient Teaching Hospital
Scott And White Memorial Hospital
Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells No dispute reported 06/30/2026 736444283
Principal investigator 1 TerSera Therapeutics LLC $97.50 08/03/2020 Covered Recipient Teaching Hospital
SCOTT AND WHITE MEMORIAL HOSPITAL
A Phase 2 Exploratory Study of Intravenous Quzyttir (Cetirizine HCl Injection) Versus IV Diphenhydramine in the Prevention of Hypersesitivity Infusion Reactions No dispute reported 06/30/2026 748252577
Principal investigator 1 Verastem, Inc. $6.16 06/30/2020 Non-covered Recipient Entity
Baylor Scott & White Medical
VS-0145-229 No dispute reported 06/30/2026 745013367
Principal investigator 1 Verastem, Inc. $2.44 06/30/2020 Non-covered Recipient Entity
Baylor Scott & White Medical
VS-0145-229 No dispute reported 06/30/2026 745013371
Principal investigator 1 Verastem, Inc. $2.94 06/30/2020 Non-covered Recipient Entity
Baylor Scott & White Medical
VS-0145-229 No dispute reported 06/30/2026 745013377
Principal investigator 1 Verastem, Inc. $105.90 06/30/2020 Non-covered Recipient Entity
Baylor Scott & White Medical
VS-0145-229 No dispute reported 06/30/2026 745013381
Principal investigator 1 Verastem, Inc. $49.35 06/30/2020 Non-covered Recipient Entity
Baylor Scott & White Medical
VS-0145-229 No dispute reported 06/30/2026 745013387
Principal investigator 1 Verastem, Inc. $54.81 06/30/2020 Non-covered Recipient Entity
Baylor Scott & White Medical
VS-0145-229 No dispute reported 06/30/2026 745013391
Principal investigator 1 Verastem, Inc. $3.48 06/30/2020 Non-covered Recipient Entity
Baylor Scott & White Medical
VS-0145-229 No dispute reported 06/30/2026 745013397
Principal investigator 1 Verastem, Inc. $43.85 06/30/2020 Non-covered Recipient Entity
Baylor Scott & White Medical
VS-0145-229 No dispute reported 06/30/2026 745013403
Principal investigator 1 TerSera Therapeutics LLC $474.86 04/08/2020 Covered Recipient Teaching Hospital
SCOTT AND WHITE MEMORIAL HOSPITAL
A Phase 2 Exploratory Study of Intravenous Quzyttir (Cetirizine HCl Injection) Versus IV Diphenhydramine in the Prevention of Hypersesitivity Infusion Reactions No dispute reported 06/30/2026 748252575
Principal investigator 1 TerSera Therapeutics LLC $16,873.00 03/19/2020 Covered Recipient Teaching Hospital
SCOTT AND WHITE MEMORIAL HOSPITAL
A Phase 2 Exploratory Study of Intravenous Quzyttir (Cetirizine HCl Injection) Versus IV Diphenhydramine in the Prevention of Hypersesitivity Infusion Reactions No dispute reported 06/30/2026 748252573
Principal investigator 1 Celgene Corporation $5,475.00 01/21/2020 Non-covered Recipient Entity
Baylor Research Institute
A SAFETY TRIAL OF LISOCABTAGENE MARALEUCEL (JCAR01 No dispute reported 06/30/2026 753808215
Principal investigator 1 Celgene Corporation $20,725.00 01/21/2020 Non-covered Recipient Entity
Baylor Research Institute
A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting No dispute reported 06/30/2026 753808217